60868-01-1

Basic information

• Product Name: 3-(4-methylpiperazin-1-yl)-1-phenylpropan-1-one
• Synonyms: 3-(4-methylpiperazin-1-yl)-1-phenylpropan-1-one
• CAS NO: 60868-01-1
• Molecular Weight: 232.326
• Mol File: 60868-01-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 3-(4-methylpiperazin-1-yl)-1-phenylpropan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-methylpiperazin-1-yl)-1-phenylpropan-1-one(60868-01-1)
• EPA Substance Registry System: 3-(4-methylpiperazin-1-yl)-1-phenylpropan-1-one(60868-01-1)

Safety Data

• Hazardous Substances Data: 60868-01-1(Hazardous Substances Data)

Upstream product

• 109-01-3 1-methyl-piperazine 
• 110-88-3 1,3,5-Trioxan 
• 64-17-5 ethanol 
• 50398-09-9 N-methylpiperazine dihydrochloride 
• 98-86-2 acetophenone 
• 50-00-0 formaldehyd 
• 936-59-4 3-chloropropiophenone 
• 768-03-6 Phenyl vinyl ketone 

Downstream Products

• 102552-21-6 N-(3,3-diphenylallyl)-N'-methylpiperazine 
• 60867-91-6 1-methyl-4-(3'-phenyl-3'-hydroxypropyl)piperazine 
• 112443-27-3 1-cyclohexyl-3-(4-methyl-piperazino)-1-phenyl-propan-1-ol 
• 94682-55-0 3-(4-methyl-piperazin-1-yl)-1,1-diphenyl-propan-1-ol 
• 133297-00-4 1-(4-methyl-piperazino)-3-phenyl-pentan-3-ol 
• 131253-14-0 4-(4-methyl-piperazino)-2-phenyl-butan-2-ol 

Relevant articles and documents

PROTEIN CROSSLINKING INHIBITOR AND USE OF THE SAME

The present invention relates to: a ketone compound having transglutaminase-inhibiting activity, which is represented by the following Formula 1, 2, or 3: wherein R1 is a substituted or unsubstituted aryl or heterocyclyl group, R2, R3, and R4 are hydrogen atoms, n is 2, X is halogen, R5 and R6 independently represent a hydrogen atom or a substituted or unsubstituted C1-C10 alkyl, aryl, or aralkyl group, wherein R5 and R6 are not hydrogen atoms at the same time, or R5 and R6 may be taken together to form a saturated or unsaturated and substituted or unsubstituted heterocyclyl group containing a nitrogen atom (N); an inhibitor of protein crosslinking comprising the compound; and a composition for preventing or treating a protein-crosslinking causative disease, which comprises the compound or the protein crosslinking inhibitor.

Hypolipidemic effects of α, β, and γ-alkylaminophenone analogs in rodents

A number of N-substituted β-alkylaminophenone derivatives including two (α- and two γ-alkylaminophenone analogs were synthesized and investigated for hypolipidemic activity in mice at 8 mg/kg/day ip. Most of these analogs were found to be significantly more active than lovastatin and clofibrate. N-Phenylpiperazinopropiophenone 16 was one of the best derivatives, lowering serum cholesterol levels 41% and serum triglyceride levels 48% after 16 days of drug administration in CF1 mice. In Sprague-Dawley rats, N-phenylpiperazinopropiophenone at 8 mg/kg/day orally also demonstrated more potent hypolipidemic activity than clofibrate, gemfibrozil, and lovastatin at their therapeutic dosage. It significantly reduced tissue cholesterol and triglyceride levels in the aorta wall tissue and lowered the cholesterol and triglyceride levels in chylomicron, very low density lipid (VLDL) and low density lipid (LDL) fractions, while it significantly elevated the cholesterol levels in high density lipid (HDL) fraction. This compound also proved to be active in lowering both cholesterol and triglyceride levels in hyperlipidemic mice and rats induced with atherogenic diet. In vitro liver acetyl coenzyme A (CoA) synthetase, 3-hydroxy-3-methyl glutaryl (HMG) CoA reductase, acyl CoA cholesterol acyl transferase (ACAT), sn-glycerol-3-phosphate acyltransferase, phosphatidylate phosphohydrolase, and hepatic lipoprotein lipase activities were significantly inhibited by N-phenylpiperazinopropiophenone from 25 to 100 μM.

Some ketonic Mannich bases.

-